Original Research Article

Rare Case of *Trichosporon mucoides* Skin Infection in an Immuno-competent Patient

Dudhat Vaibhav L.*, Maithili Kavathekar and Sonal Patil

Department of Microbiology, Microbiology and HIC, Sahyadri Speciality Labs, Pune, India

*Corresponding author

**A B S T R A C T**

*Trichosporon spp.* are ubiquitous fungi and form normal flora on skin and gastrointestinal tract of humans. There are at least nine *Trichosporon* species that are potentially pathogenic to humans. A 29 year old male visited our lab for skin scraping and examination of diffuse de-pigmented patches over both soles associated with scaling for more than a month. Skin scraping was done from both the soles. On direct KOH mount, budding yeast cells with hyphae were seen, suggestive of yeast like fungus. The culture growth was identified as *T. mucoides* by VITEK2 (Biomerieux) and based on cultural morpholopgy, microscopy and biochemical reactions. The patient was treated with oral fluconazole (200 mg qid). The lesions showed improvement. *T. mucoides* needs to be considered in differential diagnosis in such cases.

**Keywords**

Trichosporon mucoides, Skin Infection

**Article Info**

Accepted: 18 December 2016
Available Online: 10 January 2017

**Introduction**

*Trichosporon spp.* are ubiquitous yeast-like fungi found in water and soil. They are found as the normal flora on skin and gastrointestinal tract of humans (Capoor et al., 2015; Sageerabanoo et al., 2011). Previously, the species *Trichosporon beigelli* was used to represent all the pathogenic members of the genus *Trichosporon*. More recently, this species has been divided into several distinct species, based on morphological characteristics, biochemical reactions and molecular studies. There are at least 9 *Trichosporon* species that are potentially pathogenic to humans: *T. asahii*, *T. mucoides*, *T. cutaneum*, *T. inkin*, *T. ovoides*, *T. asteroids*, *T. loubieri*, *T. pullulans*, and *T. japonicum*. Out of these, *T. asahii* and *T. mucoides* have potential to cause severe life-threatening infections whereas the others usually cause superficial infections (Ağirbasli et al., 2008).

A few cases of *Trichosporon mucoides* as a cause of onychomycosis and other infections including disseminated fungemia have been published (Capoor et al., 2015; Sageerabanoo et al., 2011; Ağirbasli et al., 2008; Nettles et al., 2003; Padhi et al., 2014).

We report an unusual case of superficial skin infection on the soles of a 29 years old immuno-competent male caused by *T. mucoides*. 

315
**Case Report**

A 29 year old male visited our lab for skin scraping and examination of diffuse depigmented patches over both soles associates with scaling for more than a month.

When enquired about the related history and his lifestyle, it was learnt that the patient was often involved in outdoor sports and camping and trekking. He also has a tendency to sweat a lot. About a month and a half ago, he had gone on trekking to a near fort and had shoes on for almost a complete day. He noted scaly de-pigmented lesions on soles a week after this event.

Skin scraping was done from both the soles. On direct KOH mount, budding yeast cells with hyphae were seen, suggestive of yeast like fungus. Sample was cultured on Sobbauraud’s dextrose agar with and without antibiotic (Chloramphenicol). After 48 hours of incubation, creamy, white smooth colonies were obtained, which were positive for urea hydrolysis and identified as *T. mucoides* by VITEK2 (Biomerieux) and based on cultural morphology, microscopy and biochemical reactions.

The patient was treated with oral fluconazole (200 mg qid) and asked for follow up after two weeks. The lesions showed improvement. He was asked to continue treatment for another two weeks and follow up.

**Results and Discussion**

*T. mucoides* is currently included in the clade of *T. cutaneum*. *T. mucoides* is a more frequent cause of infections like onychomycosis as compared to other *Trichosporon* species according to studies carried out by Thérizol-Ferly et al. (Thérizol-Ferly et al., 1994; Thérizol-Ferly et al. b, 1994). *Trichosporon mucoides* has been reported from several cases of kidney, heart and liver transplant recipients (Nettles et al., 2003, Lacasse and Cleveland, 2009), premature newborns with deep infections (Go¨kahmetog˘lu et al., 2002; Silva et al., 2004), peritoneal dialysis patients (Chen et al., 2013), leukemic (Kendirli et al., 2006) and diabetics(Thérizol-Ferly et al., 1994).

The risk factors for infections *T. mucoides* include admission to an intensive care unit, antibiotic therapy, and the presence of a central venous catheter (Silva et al., 2004).

**Fig.1** Diffuse depigmented scaling lesion on right foot (Sole)
Other predisposing factors include genetic abnormalities, low socioeconomic level, old age, hyperhydrosis, climatic conditions, diabetes, immunodeficiency, atherosclerosis, and trauma (Capoor et al., 2015). Optimal therapy for *Trichosporon* infection is poorly defined (Nettles et al., 2003). At present, there are no therapeutic guidelines for treatment of systemic infections *T. mucoides*. Low level resistance has been reported against itraconazole and fluconazole (4% and 6% respectively) however amphotericin B showed 100% sensitivity (Kendirli et al., 2006). The outcome of the infection more often than not depends on the immune status of the host and the extent of the infection. Most cases of disseminated *Trichosporon* infection have been treated with amphotericin B, at times in combination with 5-fluorocytosine. This combination appears to have limited activity against *Trichosporon* fungi. Data regarding regarding the utility of lipid formulations of amphotericin is limited. On the other hand, there is growing evidence in support of use of azoles for treatment of *Trichosporon* infections (Anaissie et al., 2006).
1992). The most common fluconazole dosage used was 400 mg per day (range, 100–400 mg) for 2–26 weeks. These patient was treated with oral fluconazole (200 mg qid) and showed evidence of improvement after 15 days. The plan of treatment is to continue with oral fluconazole for another 6–8 weeks with follow up after every 2 weeks.

In conclusion, *T. mucoides*, though a rare entity causing superficial skin infections, needs to be considered as a differential diagnosis in such cases.

References


How to cite this article: